Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 3 2Phase 1/2 2

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Myeloid 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma 2Recurrence 1Myeloproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

pembrolizumab 524Specimen Handling 383Carboplatin 377Magnetic Resonance Spectroscopy 336Cisplatin 332Nivolumab 308Cyclophosphamide 298Radiotherapy 257Paclitaxel 255Gemcitabine 235Biopsy 235Bevacizumab 218Dexamethasone 169durvalumab 168Oxaliplatin 163Capecitabine 158Rituximab 157Fluorouracil 149venetoclax 147Docetaxel 147Etoposide 142Drug Therapy 142atezolizumab 141Doxorubicin 134Ipilimumab 129Radiosurgery 120Prednisone 120Lenalidomide 119Leucovorin 113fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × parsaclisib × 1 year × Clear all
NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Incyte Corporation

Phase 2 Active not recruiting
112 enrolled
LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT02998476 2025-08-22

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Incyte Corporation

Phase 2 Completed
60 enrolled 15 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03144674 2025-07-11

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Incyte Corporation

Phase 2 Completed
110 enrolled 18 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡